Making Your List & Checking It Twice: Considerations for Orange Book Listing in light of Recent Court Decisions

35th Annual Pharmaceutical/Chemical Patent Practice Update Webinar Series

Earn up to 1.0 Professional CLE for NJ/NY/PA

Charanjit Brahma, Partner, Benesch Friedlander Coplan & Aronoff LLP, will first briefly discuss the basic requirements for listing patents in the Orange Book and their interplay with 35 U.S.C. § 271(e), which is commonly the basis for lawsuits alleging infringement of listed patents. He will then discuss recent cases that highlight some of the potential issues surrounding listing decisions, including the multiple Federal Circuit decisions in GSK v. Teva and the Second Circuit’s recent decision in UFCW Local 1776 v. Takeda regarding the potential antitrust consequences of improperly listing patents in the Orange Book. Finally, he will provide some practical guidance that branded and generic companies should consider in building and assessing listed patent portfolios and developing litigation strategies.

Member Free | Non-Member $45.00

PANELISTS

Charanjit Brahma, Partner, Benesch Friedlander Coplan & Aronoff LLP

Charanjit Brajma focuses his practice on patent litigation and other intellectual property matters, primarily for pharmaceutical and technology clients. His trial focus helps him work with clients to craft efficient litigation strategies that meet their business objectives. [Read more]

Zoom Note: Once you register, you will receive a Zoom confirmation e-mail with a unique link to join the session. Click "Add to calendar" to ensure you don't miss the webinar.

Chemical Practice Co-Chairs J. Eric Thies, Organon & Co. and Suja Vathyam, Botos Churchill IP Law LLP

Thank you to our Sponsor